Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non–Small Cell Lung Cancer: Independent Review of Four PROFILE Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non–Small Cell Lung Cancer: Independent Review of Four PROFILE Trials

Published:2017-09 Issue:5 Volume:18 Page:472-479
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Yoneda Ken Y.,Scranton Judith R.,Cadogan Michael A.,Tassell Vanessa,Nadanaciva Sashi,Wilner Keith D.,Stollenwerk Nicholas S.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma;Christensen;Mol Cancer Ther,2007

2. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

3. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. ASCO meeting abstracts;Crino;J Clin Oncol,2011

4. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO meeting abstracts;Kim;J Clin Oncol,2012

5. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of brigatinib following alectinib-induced-pneumonitis: Case report;2024-08-09

2. Lung Injury Induced by Crizotinib and Entrectinib in a Patient with <i>ROS1</i>-rearranged Non-small-cell Lung Cancer;Internal Medicine;2023-12-01

3. Pharmacovigilance for rare diseases: a bibliometrics and knowledge-map analysis based on web of science;Orphanet Journal of Rare Diseases;2023-09-26

4. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis;Frontiers in Immunology;2023-09-20

5. Drug-Induced Interstitial Lung Diseases;Immunology and Allergy Clinics of North America;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3